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Representatives of Actinobacteria were isolated from the marine sponge Halichondria panicea collected from
the Baltic Sea (Germany). For the first time, a comprehensive investigation was performed with regard to
phylogenetic strain identification, secondary metabolite profiling, bioactivity determination, and genetic ex-
ploration of biosynthetic genes, especially concerning the relationships of the abundance of biosynthesis gene
fragments to the number and diversity of produced secondary metabolites. All strains were phylogenetically
identified by 16S rRNA gene sequence analyses and were found to belong to the genera Actinoalloteichus,
Micrococcus, Micromonospora, Nocardiopsis, and Streptomyces. Secondary metabolite profiles of 46 actinobac-
terial strains were evaluated, 122 different substances were identified, and 88 so far unidentified compounds
were detected. The extracts from most of the cultures showed biological activities. In addition, the presence of
biosynthesis genes encoding polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs) in
30 strains was established. It was shown that strains in which either PKS or NRPS genes were identified
produced a significantly higher number of metabolites and exhibited a larger number of unidentified, possibly
new metabolites than other strains. Therefore, the presence of PKS and NRPS genes is a good indicator for the
selection of strains to isolate new natural products.
Sponges are multicellular invertebrates and sessile filter
feeders which are abundant in the oceans as well as in fresh-
water habitats (41). They gained great interest due to their
association with a wide variety of microorganisms. These mi-
croorganisms are known to be a rich source of secondary me-
tabolites (108), which exhibit a broad range of bioactivities
such as inhibition of enzyme activities and cell division and
antiviral, antimicrobial, anti-inflammatory, antitumor, cyto-
toxic, and cardiovascular properties (77).
Numerous studies concerning specific aspects of sponge-
bacterium associations were accomplished using distinct meth-
ods for the evaluation of the microbial diversity (mostly mo-
lecular approaches) or the bioactivities (culture-dependent
methods) or biosynthetic aspects (chemical analyses and mo-
lecular approaches) of secondary metabolites of the associated
bacteria (19, 47, 51, 54, 110, 122, 126). So far, there is less
comprehensive information about the integration of this
knowledge into concepts for sponge-bacterium interactions
based on small molecules.
We focused on Actinobacteria associated with Halichondria
panicea Pallas (Porifera, Demospongiae, Halichondriida, Hali-
chondriidae), a sponge species living in coastal habitats world-
wide (9). Previous work demonstrated a phylogenetically
diverse array of bacterial groups present in this sponge: rep-
resentatives of Alphaproteobacteria, Betaproteobacteria, Gam-
maproteobacteria, Cytophaga/Flavobacteria, the Deinococcus
group, low-GC-content Gram-positive bacteria, Actinobacte-
ria, and Planctomycetales were identified by means of a genetic
approach (47, 122). Among these, though representing only 3
to 20% of the sponge-associated bacterial community (41, 47,
103), Actinobacteria are the most promising bacterial group
regarding secondary metabolite production. Members of this
phylum account for approximately half of the bioactive sec-
ondary metabolites that have so far been discovered in bacteria
(64). Although the majority of secondary metabolite-produc-
ing Actinobacteria originate from terrestrial habitats (101), re-
cent studies of marine Actinobacteria have revealed many new
chemical entities and bioactive metabolites (13, 30, 50, 100).
Among these, only a few substances were isolated from Acti-
nobacteria associated with H. panicea (85, 123), e.g., the anti-
microbially active substances 2,4,4-trichloro-2-hydroxydiphe-
nylether and acyl-1-(acyl-6-mannobiosyl)-3-glycerol produced
by Micrococcus luteus (17). By combining data about the phy-
logenetic characterization of the Actinobacteria associated with
H. panicea, their biosynthetic potential for secondary metabo-
lite production, and their chemical profiles, we present com-
prehensive insights into a great variety of produced natural
products as well as their bioactivities. By means of these re-
sults, we attempt to close the gap of knowledge about Acti-
nobacteria associated with H. panicea and discuss the biological
roles of identified small molecules in the sponge-associated
community.
MATERIALS AND METHODS
Collection of sponges. Living specimens of H. panicea Pallas (Porifera, Demo-
spongiae, Halichondriida, Halichondriidae) used in this study were collected
several times from November 2002 to June 2004 at the Kiel Fjord, Baltic Sea
(Germany), by scuba diving. Additionally, samples of H. panicea for the inves-
tigation of the metabolite pattern were collected in October 2009 at the Kiel
Fjord.
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Isolation and identification of antimicrobially active Actinobacteria. Approxi-
mately 1 g of sponge material was macerated in sterilized habitat water, and the
suspension was plated onto five different media according to the method of
Wiese et al. (124). Pure cultures were obtained by subsequent plating steps on
tryptic soy broth (TSB) medium A (with 10 g/liter NaCl). Incubation was at 22°C
in the dark. For storage, pure cultures were kept at 80°C using the Cryobank
System according to the instructions of the manufacturer (Mast Diagnostica
GmbH, Reinfeld, Germany). Antibiotic activities of the living cultures were
determined by an overlay assay as described by Wiese et al. (124) using Bacillus
subtilis (DSM 347), Escherichia coli K-12 (DSM 498), Staphylococcus lentus
(DSM 6672), and Candida glabrata (DSM 6425) as test strains. Antibiotically
active strains were selected for the present study. To identify all strains, 16S
rRNA gene sequence analyses were carried out according to the protocol of
Thiel et al. (110). Comparison of the 16S rRNA gene sequences of the sponge-
derived strains was performed using the Basic Local Alignment Search Tool
(nucleotide blast) with the EMBL nucleotide database available at the European
Bioinformatics Institute website (http://www.ebi.ac.uk/) (2) and the Ribosomal
Database Project II (RDP-II) website (21).
Identification of NRPS and PKS-II gene fragments. All bacterial strains were
screened for genes corresponding to the nonribosomal peptide synthetase
(NRPS) adenylation domain and the polyketide synthase type II (PKS-II) KS
domain by the methods developed by Doekel and Marahiel and Metsa¨-Ketela¨ et
al. (24, 73). The PCR products had expected sizes of 250 to 270 bp (for NRPS
gene fragments) and 580 to 620 bp (for PKS gene fragments). Sequences of these
PCR products were compared with NRPS and PKS sequences in the EMBL
nucleotide database available at the European Bioinformatics Institute website
by using the Basic Local Alignment Search Tool (blastx) (2).
Cultivation of liquid cultures. For the analyses of secondary metabolite pro-
files, bacteria were grown in 300-ml Erlenmeyer flasks each containing 100 ml of
medium GYM4 (10 g glucose, 4 g yeast extract, 4 g malt extract, 1 liter water, pH
7.2) for 5 days at 28°C with shaking (at 120 rpm) in the dark. Each culture was
inoculated separately with a 1-cm2 piece from a culture grown on a GYM4 agar
plate for 4 weeks at 28°C in the dark.
Extraction of liquid cultures. The entire culture broth (100 ml) was extracted
by homogenization with 50 ml ethyl acetate by using an Ultra-Turrax T25 basic
disperser (IKA-Werke GmbH and Co., Staufen, Germany) at 13,000 rpm for
30 s. The supernatants were separated, dried, and subsequently resolved in
methanol. These crude extracts were used for antimicrobial assays and chemical
analyses.
Extraction of sponge specimens. Approximately 100 g wet sponge tissue was
extracted by homogenization with 500 ml methanol by using an Ultra-Turrax T25
basic disperser (IKA-Werke GmbH and Co., Staufen, Germany) at 13,000 rpm.
Afterwards the homogenate was stirred overnight at room temperature. The
resulting supernatant was separated from the cell residue, dried in vacuo, and
subsequently resolved in 5 ml methanol. These crude extracts were used for the
chemical analysis.
Antimicrobial activities of culture extracts. Antimicrobial assays were per-
formed with the following test organisms: B. subtilis (DSM 347), E. coli K-12
(DSM 498), S. lentus (DSM 6672), Pseudomonas syringae pv. aptata (DSM
50252), Pseudomonas fluorescens (NCIMB 10586), Xanthomonas campestris
(DSM 2405), Ralstonia solanacearum (DSM 9544), C. glabrata (DSM 6425), and
Erwinia amylovora (DSM 50901). Assay mixtures were prepared by transferring
10-l aliquots of methanolic solutions of extracts or pure substances into two
wells of a 96-well microtiter plate and evaporating the solvent in a vacuum
centrifuge. Overnight cultures of the test organisms in TSB medium (tryptic soy
broth [Difco], 12 g/liter; NaCl, 5 g/liter) were diluted to an optical density at 600
nm (OD600) of 0.02 to 0.05, and 200-l aliquots of the resulting suspensions were
added to the wells. After incubation for 15 h at 600 rpm and 28°C, 10 l of a
resazurin solution (0.2 mg/ml phosphate-buffered saline) was added to each well
and the plate was incubated at 28°C until the color of the negative control
changed from blue to pink. For evaluation of the cell viability, the transformation
of resazurin to resorufin was assayed by measuring the fluorescence at 560 nm
after excitation at 590 nm. The resulting values were compared to those for a
positive control (100 g/well chloramphenicol for bacteria and 200 g/well cy-
cloheximide for Candida) and a negative control (no compound) on the same
plate.
Chemical analyses of culture extracts and sponge extract. Dereplication of
substances was realized by comparison of mass spectrometry (MS) and UV data
obtained by high-performance liquid chromatography (HPLC)-UV/MS analyses.
Reversed-phase HPLC experiments were performed by using a Phenomenex
Onyx Monolithic C18 column (100 by 3.00 mm) and applying an H2O (solvent
A)-acetonitrile (MeCN; solvent B) gradient with 0.1% HCOOH added to both
solvents (gradient program: 0 min, 5% solvent B; 4 min, 60% solvent B; 6 min,
100% solvent B; flow, 2 ml/min) on a VWR Hitachi Elite LaChrom system
coupled to an electrospray ionization (ESI) ion trap detector (Esquire 4000;
Bruker Daltonics). The resulting chemical data were compared with data from
the Antibase (63) and the Chapman & Hall/CRC Chemical Database Dictionary
of Natural Products (15). Several extracts were subjected to preparative HPLC
with a Phenomenex Gemini-NX C18 column (5 m, 110 Å, Axia packed; 100 by
21.20 mm) and variable gradients of eluents H2O (solvent A) and MeCN (solvent
B). For selected substances, a 1H nuclear magnetic resonance (NMR) analysis
was carried out. NMR spectra were recorded on a Bruker AV 600 spectrometer
(at 600 and 150 MHz) by using the signals of the residual solvent protons as
internal references (chemical shift H 3.31 ppm for protons and C 49.0 ppm for
carbons; NMR solvent, deuterium-labeled methanol [MeOH-D4]). High-resolu-
tion mass spectra were acquired on a benchtop time-of-flight spectrometer
(MicrOTOF; Bruker Daltonics) with positive ESI.
Nucleotide sequence accession numbers. The nucleotide sequence data re-
ported in the present study were deposited in the GenBank nucleotide sequence
database under the accession numbers GQ863900 to GQ863929, GQ863931 to
GQ863933, GU213489 to GU213493, and GU213495 to GU213502 (for 16S
rRNA sequences), GQ863946 to GQ863965 (for NRPS sequences), and
GQ863934 to GQ863945 and GU320045 (for PKS sequences).
RESULTS
Isolation and identification of Actinobacteria from H. pani-
cea. Among a large number of bacteria isolated from the
sponge H. panicea, 46 isolates were classified as Actinobacteria
belonging to the genera Actinoalloteichus, Micrococcus, Mi-
cromonospora, Nocardiopsis, and Streptomyces, with members
of the last genus, comprising 39 strains, being the most abun-
dant (Table 1).
Identification of NRPS and PKS-II gene fragments. All ac-
tinobacterial strains were analyzed for the presence of PKS-II
and NRPS genes (Table 1; see also the supplemental material).
In 16 strains (35%), neither NRPS nor PKS gene fragments
were detected. An NRPS PCR product of the expected size
was recovered from 24 strains (52%), and 20 of these products
had sequences similar (40 to 96%) to known NRPS gene frag-
ments. These similarities give basic information on the pres-
ence of NRPS genes, but correlation to specific metabolites is
limited due to the lengths of the PCR fragments. The PCR
products of four strains showed more than one sequence with
similar lengths in the electropherogram, indicating multiple
NRPS gene clusters.
PKS sequences with similarities to known PKS gene frag-
ments were obtained from 13 (28%) of the Actinobacteria
strains (see the supplemental material). Similarities between
the gene sequences of the investigated Actinobacteria and
known sequences ranged from 47% (for a sequence from strain
HB328 and the ketosynthase gene sequence from Streptomyces
felleus BAF43343) to 100% (for a sequence from strain HB202
and a PKS sequence from Streptomyces sp. BAH68110). For 7
strains (15%), PCR products for both PKS-II and NRPS genes
were detected.
Chemical analyses of culture extracts. The Actinobacteria
strains isolated from H. panicea turned out to be potent pro-
ducers of secondary metabolites, with 40 of 46 strains produc-
ing detectable amounts of metabolites. In total, 122 different
substances were identified from the secondary metabolite pat-
terns of the analyzed Actinobacteria strains by using HPLC-
MS, UV, and NMR techniques (Tables 2 and 3). The numbers
and diversity of produced compounds indicated by the metab-
olite profiles were evaluated with respect to the presence
of PKS and NRPS biosynthetic genes. A much higher level of
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diversity of natural products was found in strains with proof of
PKS or NRPS genes than in those with negative PCR results
(23 different structural groups versus 7 different structural
groups) (Fig. 1). Strains exhibiting no PKS-II or NRPS ampli-
cons synthesized only a small spectrum of compounds, mainly
antimycin derivatives. In the 30 Actinobacteria strains with pos-
itive PCR results for PKS genes (13 strains) and/or NRPS
genes (24 strains), a total of 108 different substances were
identified. In only one of these strains, no metabolite could be
detected, while 17 strains (57%) produced substances (a total
of 88 compounds) that have not been identified so far and are
probably new natural products (Table 1). Elucidation of the
structures of these compounds is in progress. Among the 16
strains which gave no hints of the presence of PKS-II or NRPS
TABLE 1. Actinobacteria from H. panicea: identification, detection of PKS-II and NRPS gene fragments, and chemical analyses
Strain Most closely related type straina
16S rRNA gene
sequence
accession no.b
Gene fragment(s) identified
Chemically
identified
product(s)c
Detection of
new
compound(s)d
HB062 Streptomyces griseus ATCC 25497 D63872 PKS and NRPS fragments Other X
HB084 Streptomyces intermedius DSM 40372 Z76686 Other
HB094 Streptomyces sampsonii ATCC 25495 D63871
HB095 Streptomyces rutgersensis DSM 40077 Z76688 Other
HB096 Streptomyces rutgersensis DSM 40077 Z76688 Other
HB099 Streptomyces griseus ATCC 25497 D63872 X
HB100 Streptomyces platensis JCM 4662 AB045882 PKS and NRPS fragments Other
HB101 Streptomyces libani subsp. rufus LMG 20087 AJ781351 NRPS fragment Pep
HB102 Streptomyces scabiei ATCC 49173 D63862 NRPS fragment Other
HB105 Streptomyces sampsonii ATCC 25495 D63871 Other
HB107 Streptomyces platensis JCM 4662 AB045882 NRPS fragment Other, pep X
HB108 Streptomyces fulvorobeus LMG 19901 AJ781331
HB110 Streptomyces griseus ATCC 25497 D63872
HB113 Streptomyces fulvorobeus LMG 19901 AJ781331 PKS and NRPS fragmentse Other, pep X
HB114 Streptomyces griseus ATCC 51928 AF112160
HB115 Streptomyces mediolani LMG 20093 AJ781354 X
HB116 Streptomyces sampsonii ATCC 25495 D63871 Other, arom pk
HB117 Streptomyces fulvorobeus LMG 19901 AJ781331 PKS fragment Other
HB118 Streptomyces sampsonii ATCC 25495 D63871 Other, arom pk
HB122 Streptomyces luridiscabiei S63 AF361784 Other
HB132 Streptomyces atroolivaceus LMG 19306 AJ781320 PKS and NRPS fragmentse Other X
HB138 Streptomyces fulvorobeus LMG 19901 AJ781331 NRPS fragment Other, pep X
HB140 Streptomyces griseus ATCC 25497 D63872 NRPS fragment Other, pep
HB142 Streptomyces intermedius DSM 40372 Z76686 NRPS fragment Other X
HB149 Streptomyces griseus JCM 4623 AB045872 NRPS fragment X
HB156 Streptomyces koyangensis VK-A60 AY079156 NRPS fragment Other
HB157 Streptomyces sampsonii ATCC 25495 D63871 NRPS fragment Other, arom pk
HB181 Streptomyces fulvorobeus LMG 19901 AJ781331 NRPS fragment Other, pep X
HB184 Streptomyces mediolani LMG 20093 AJ781354 Other
HB200 Streptomyces pulveraceus LMG 20322 AJ781377 PKS and NRPS fragmentse Other X
HB202 Streptomyces mediolani LMG 20093 AJ781354 PKS and NRPS fragments Other X
HB238 Micromonospora matsumotoense IMSNU
22003
AF152109 NRPS Pepf
HB241 Micrococcus luteus ATCC 4698 AF542073 Other
HB243 Streptomyces mediolani LMG 20093 AJ781354 NRPS fragment Other, pep
HB253 Micromonospora matsumotoense IMSNU
22003
AF152109 NRPS fragmente X
HB254 Micromonospora matsumotoense IMSNU
22003
AF152109 X
HB272 Actinoalloteichus cyanogriseus C7654 AY094367 NRPS fragment Other, pep X
HB274 Streptomyces platensis JCM 4662 AB045882 NRPS fragment X
HB288 Streptomyces odorifer DSM 40347 Z76682 NRPS fragment Other, pep
HB291 Streptomyces fulvorobeus LMG 19901 AJ781331 PKS and NRPS fragments Other X
HB298 Streptomyces coelescens ICSSB 1021 AF503496 PKS fragment Other
HB320 Streptomyces sanglieri A5843 AY094363 PKS fragment Other, arom pk X
HB328 Streptomyces fulvorobeus LMG 19901 AJ781331 PKS fragment Other
HB375 Micromonospora aurantiaca DSM 43813 X92604 NRPS fragment Other X
HB381 Streptomyces griseus ATCC 2549 D63872 PKS fragment
HB383 Nocardiopsis alba DSM 43377 X97883 PKS fragment X
a The analyzed sequences from each strain and the corresponding type strain had a level of similarity greater than or equal to 98.5%.
b NCBI accession number.
c Pep, peptide; arom pk, aromatic polyketide; other, secondary metabolite(s) other than a peptide or aromatic polyketide. Identified compounds are listed in Tables
2 and 3.
d X indicates the occurrence of a new compound.
e A PCR product(s) in the expected size range was obtained. Affiliation of the obtained sequence to known genes was not possible.
f Proven NRPS biosynthetic pathway.
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TABLE 2. Identified metabolites from H. panicea-associated actinobacterial strains positive for a PKS and/or NRPS gene fragment by PCR
No. Source(s) Compound (reference) Chemical group Activity(ies) Dereplication analyses
1 HB062 6-O--D-Mannopyranosylmannosido-
streptomycin (45)
Aminoglycoside Antibacterial MS, UV
2 HB100 Oxazolomycin (53) -Lactone, polyene Phytotoxic MS, UV, NMR
3 HB100 Coproporphyrin (113) Porphyrin Zinc chelator,
photosensitizer
MS, UV
4 HB101 Pepstatin AC (5) Peptide Pepsin inhibitor MS, UV, NRPS-specific PCR
5 HB101 Pepstatin CU (5) Peptide Pepsin inhibitor MS, UV, NRPS-specific PCR
6 HB102 Clavamycin D (57) -Lactam antibiotic Antifungal MS, UV
7 HB107 4-Thiouracil (25) Nucleoside analog Antibacterial, cytotoxic MS, UV
8 HB107 Bovinocidin (4) Dipeptide Antibacterial MS, UV, NRPS-specific PCR
9 HB107 Trihomononactic acid (93) Lactone Active against Gram-positive
bacteria and brine shrimp
MS, UV
10 HB113, HB272 Antibiotic NA 22598A1 (62) Peptide Cytotoxic MS, UV, NRPS-specific PCR
11 HB113, HB140 3-O-(-L-Mycarosyl)erythronolide B (71) Macrolide NDa MS, UV
12 HB113 Gualamycin (114) Aminoglycoside Acaricidal MS, UV
13 HB113 Antibiotic X 14931A (120) Polyether Active against Gram-positive
bacteria, fungi, and
protozoa
MS, UV
14 HB113 17-Methylenespiramycin I (68) Macrolide ND MS, UV
15 HB113 Streptomycin (116) Aminoglycoside Antibacterial, neuromuscular
blocking agent,
phospholipase D inhibitor
MS, UV
16 HB113 Antibiotic M-2846 (105) Macrolide Active against Gram-positive
bacteria
MS, UV
17 HB113 1-Epimanzamine D (127) Alkaloid Antibacterial, cytotoxic MS, UV
18 HB113 Antibiotic A 75943 (75) -Lactone Bone resorption inhibitor MS, UV
19 HB113 N-Didemethylallosamidin (81) Aminoglycoside Chitinase inhibitor,
insecticide, antifungal
MS, UV
20 HB113 Methylallosamidin (99) Aminoglycoside Insect chitinase inhibitor MS, UV
21 HB113 Allosamidin (99) Aminoglycoside Insecticide MS, UV
22 HB117, HB291 Dihydromaltophilin (34) Macrolactam Antifungal MS, UV
23 HB117, HB181, HB291 Senacarcin A (79) Phenazine Antibacterial, cytotoxic MS, UV
24 HB117, HB328 Pyrocoll (22) Alkaloid Antibacterial, antifungal,
cytotoxic, antiprotozoan,
antiparasitic
MS, UV, NMR
25 HB117, HB291 Streptazone B1 (90) Alkaloid Cytotoxic MS, UV
26 HB132 Venturicidin A (95) Macrolide Antifungal MS, UV
27 HB132 Irumamycin (83) Lactone Antifungal MS, UV
28 HB138 Bundlin A (115) Macrolide Active against Gram-positive
bacteria and fungi
MS, UV
29 HB138 Neoenactin B1 (98) Hydroxamic acid Antifungal MS, UV
30 HB138 Ashimycin A (112) Aminoglycoside Antibacterial MS, UV
31 HB138 Validamycin D (42) Aminoglycoside Antifungal MS, UV
32 HB138 N-Demethylstreptomycin (31) Aminoglycoside Antimicrobial MS, UV
33 HB138 Detoxin E1 (84) Depsipeptide Cytotoxic MS, UV
34 HB138 Antibiotic X 14873A (67) Polyether Active against Gram-positive
bacteria
MS, UV
35 HB138 Valistatin (58) Tripeptide Aminopeptidase M inhibitor MS, UV, NRPS-specific PCR
36 HB140 Phencomycin ethyl ester (91) Phenazine Antibacterial, cytotoxic MS, UV
37 HB140 Pepstatin BU (5) Peptide Pepsin inhibitor MS, UV, NRPS-specific PCR
38 HB140 N-Acetylglycylclavaminic acid (6, 92) -Lactam -Lactamase inhibitor MS, UV
39 HB142, HB156 Isovaleryl-6-deoxy--L-talopyranoside (11) Glycoside ND MS, UV
40 HB156 Polyene with 8 or 9 double bonds Polyene Antifungal MS, UV
41 HB156 Galbonolide A (28) Macrolide Antifungal MS, UV
42 HB156, HB291 5-Hydroxy-3-(1-hydroxy-2-methylpropyl)-
4-methyl-2(5H)-furanone (14)
Lactone Antibacterial, chitinase and
phosphatase inhibitor
MS, UV
43 HB156 Albaflavenone (36) Sesquiterpene
ketone
Antibacterial MS, UV
44 HB157 3,4-Dimethyl-7-(methylamino)-5,8-
isoquinolinedione (70)
Quinone Active against Gram-positive
bacteria
MS, UV
45 HB157, HB288 5-(6-Methyl-7-oxo-octyl)-SH-furan-2-one
(76)
Lactone Cytotoxic MS, UV, NMR
46 HB157 Polyene with 7 or 8 double bonds Polyene Antifungal MS, UV
47 HB157 Fredericamycin A (117) Aromatic
polyketide
Cytotoxic generator of free
radicals
MS, UV
48 HB157, HB181 Antimycin A4 (8) Macrolide Inhibitor of ATP-citrate
lyase
MS, UV, NMR
49 HB157, HB181, HB288 Antimycin A3 (8) Macrolide Cytotoxic, antiviral, inhibitor
of ATP-citrate lyase
MS, UV, NMR
50 HB157, HB181, HB288 Antimycin A2 (8) Macrolide Inhibitor of ATP-citrate
lyase
MS, UV, NMR
Continued on following page
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TABLE 2—Continued
No. Source(s) Compound (reference) Chemical group Activity(ies) Dereplication analyses
51 HB157, HB181, HB288 Antimycin A1 (8) Macrolide Antiviral inhibitor of ATP-
citrate lyase, ichthyotoxin,
inhibitor of ubiquinol-
cytochrome C
oxidoreductase
MS, UV, NMR
52 HB157 Antimycin A0 (8) Macrolide Antifungal MS, UV, NMR
53 HB157 Antimycin A5 (8) Macrolide ND MS, UV, NMR
54 HB181 Histidinomycin (48) Peptide Antifungal MS, UV, NRPS-specific PCR
55 HB181 Nebramycin (111) Aminoglycoside Antimicrobial MS, UV
56 HB181, HB243 Antibiotic X 14873G (67) Polyether Active against Gram-positive
bacteria
MS, UV
57 HB181 Mycospocidin (78) Nucleoside Active against Gram-positive
bacteria
MS, UV
58 HB181 5-Hydroxy-4-oxonorvaline (52) Amino acid Antifungal MS, UV
59 HB181 3-Formamido-2-hydroxy-N-
	(2R,6S,7R,8R)-7-hydroxy-2,6,8-
trimethyl-4,9-dioxo-1,5-dioxonan-3-
yl
benzamide (37)
Macrolide
(antimycin)
ND MS, UV
60 HB181 N-	(2R,3S,6S,7R,8R)-8-Ethyl-7-hydroxy-
2,6-dimethyl-4,9-dioxo-1,5-dioxonan-3-
yl
-3-formamido-2-hydroxybenzamide
(37)
Macrolide
(antimycin)
ND MS, UV
61 HB181 Blastamycin (37) Macrolide
(antimycin)
Antifungal, inhibitor of
ATP-citrate lyase
MS, UV
62 HB181 Kitamycin A (39) Macrolide
(antimycin)
Plant growth inhibitor MS, UV
63 HB181 5-{3-	(3-Formamido-2-
hydroxybenzoyl)amino
-2,6-dimethyl-8-
octyl-4,9-dioxo-1,5-dioxonan-7-yl}
pentanoic acid (37)
Macrolide
(antimycin)
ND MS, UV
64 HB181 Bafilomycin D (60) Macrolide Inhibitor of membrane
ATPases, insecticide
MS, UV
65 HB200 Antibiotic BE 10988 (82) Thiazolylindole Cytotoxic, topoisomerase II
inhibitor
MS, UV, NRPS-specific
PCRb
66 HB200 N-Methyltyrosyl-N-
methyltyrosylleucylalanin (3)
Peptide ND MS, UV
67 HB202 Streptophenazin A (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
68 HB202 Streptophenazin B (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
69 HB202 Streptophenazin C (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
70 HB202 Streptophenazin D (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
71 HB202 Streptophenazin E (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
72 HB202 Streptophenazin F (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
73 HB202 Streptophenazin G (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
74 HB202 Streptophenazin H (74) Phenazine Active against Gram-positive
bacteria
MS, UV, NMR
75 HB238 Rotihibin B (32) Peptide Plant growth regulator MS, UV, NRPS-specific PCR
76 HB238 Heptakis-(6-deoxy)-cyclomaltoheptose
(15)
Glycoside ND MS, UV
77 HB238 Antibiotic GAI 3 (15) Glycoside ND MS, UV
78 HB238 Antibiotic GAI 2 (15) Glycoside ND MS, UV
79 HB238 Fortimicin KR1 (107) Aminocyclitol Antibacterial MS, UV
80 HB238 Massetolide K (26) Lipopeptide Antibacterial MS, UV, NRPS-specific PCR
81 HB243 Sulfostin (1) Alkaloid Inhibitor of dipeptidyl
peptidase IV
MS, UV
82 HB243 Fosfazinomycin A (35) Aminophosphonic
acid
Antifungal MS, UV
83 HB243 Tobramycin (59) Aminoglycoside Antibacterial MS, UV
84 HB243 N-Acetylvalylleucylargininal (69) Peptide ND MS, UV, NRPS-specific PCR
85 HB272 Hemipyocyanine (102) Phenazine Active against Gram-positive
bacteria, antifungal,
antiviral, algicide
MS, UV
86 HB272 Daryamide C (7) Polyketide Cytotoxic MS, UV
87 HB272 Antibiotic A 58365B (80) Nucleoside Cytotoxic MS, UV
88 HB272 Antibiotic SW 163B (106) Octadepsipeptide Antifungal,
immunosuppressant
MS, UV
89 HB274 Dihydro-4-(hydroxymethyl)-3-(3-
methylbutanonyl)-2(3H)-furanone (15)
Furanone ND MS, UV
Continued on following page
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genes, 4 strains (25%) did not produce any detectable metab-
olite, while in the remaining 12 strains, a total of 27 compounds
were identified. Only 3 of those 12 metabolite-producing bac-
teria were capable of the biosynthesis of natural products (a
total of 11 compounds) not listed in any database used (Ta-
ble 1).
The identified substances belong to 23 different structural
groups. Most frequent were polyketides (35 compounds), pep-
tides (16 compounds), phenazines (13 compounds), and ami-
noglycosides (13 compounds). In total, 77 substances belonged
to these 4 most prominent structural groups; the other 19
structural groups were represented by only one or a few me-
tabolites (Fig. 1). For example, only strain HB298 produced a
single pyrone. Just four glycosides were identified; one of these
was heptakis-(6-deoxy)-cyclomaltoheptose, produced by strain
HB238.
Although specific prediction of products of NRPS and PKS
genes according to the obtained sequences is problematic, be-
cause only small gene fragments were amplified, an attempt
was made to correlate the structural properties of produced
secondary metabolites with the presence of PKS-II and NRPS
genes. Even though we expected aromatic polyketides in 13
strains (Table 1) with a matching sequence for a PKS-II gene,
aromatic polyketides were identified in only 3 strains. Strain
HB320 produced two aromatic polyketides, antibiotic K 502A
and blanchaquinone. Strains HB062 and HB202 produced pos-
sibly new aromatic polyketides. In 10 of the strains yielding
PCR products with the PKS-specific primers, no corresponding
PKS products were found under the applied culture condi-
tions. On the other hand, the strains HB116, HB118, and
HB157 produced the aromatic polyketide fredericamycin A
and strain HB184 produced enterocin, although the presence
of PKS-II genes in these strains could not be confirmed. Of 20
Actinobacteria strains containing NRPS gene fragments, 11
were shown to produce one or more peptides. For example,
strain HB238 produced massetolide K (Table 2), a known
lipopeptide which has been reported to be NRPS derived.
Chemical analysis of sponge extract. We were able to detect
the substances fosfazinomycin and tobramycin in the metha-
nolic extract from H. panicea. These two substances were sec-
ondary metabolites identified in strain HB243.
Antimicrobial activities of culture extracts. All strains were
selected according to their antibiotic activities by an overlay
assay. Subsequently, only 31 (67%) of 46 culture extracts
showed activity against at least one of the test strains (Table 4).
Frequent activities against B. subtilis (44% extracts), S. lentus
(33%), R. solanacearum (24%), and C. glabrata (26%) were
detected. More rarely, activities against E. coli (9%), P. fluo-
rescens (7%), P. syringae (9%), X. campestris (15%), and E.
amylovora (9%) were observed. The extracts revealed 18 dif-
ferent activity patterns ranging from no activity at all to activ-
ities against even seven of nine test organisms, as illustrated in
Table 4. In 15 crude extracts, we were not able to find any
microbial activity. Eight (53%) of these extracts additionally
did not show any substance in the chromatogram (Tables 1 and
4). Eleven (73%) of the 15 extracts with no antimicrobial
activity did not show any NRPS or PKS gene fragment. Seven
(47%) yielded neither antimicrobial activity nor a gene frag-
ment.
Bioactivities of identified compounds known from litera-
ture. Data on the biological activities of most of the secondary
metabolites isolated from Actinobacteria and identified via
HPLC-UV/MS analyses in this study were compiled by a pro-
found literature search concerning reported biological activi-
ties (e.g., antibacterial, antifungal, cytotoxic, immunosuppres-
sive, antiviral, and algicidic). The results are summarized in
Tables 2 and 3. In particular, activities against Gram-positive
bacteria and fungi as well as cytotoxic activities were described
for a number of these metabolites. However, in some extracts,
metabolites with exceptional activities, like rotihibin B from
TABLE 2—Continued
No. Source(s) Compound (reference) Chemical group Activity(ies) Dereplication analyses
90 HB274 4-Hydroxythreonine (121) Amino acid Antibacterial MS, UV
91 HB288 Albopeptin A (49) Peptide Antifungal MS, UV, NRPS-specific PCR
92 HB288 PD 125375 (96) Pyrrol, amide Cytotoxic MS, UV
93 HB291 Lankamycin (33) Macrolide Antibacterial MS, UV
94 HB298 Germicidin (86) Pyrone Retards germination of
cress; inhibitor of porcine
Na/K-activated ATPase
MS, UV, NMR
95 HB298 Inthomycin A (118) Polyketide Antimicrobial, herbicidal MS, UV, NMR
96 HB298 Inthomycin B or C (40) Polyketide ND MS, UV, NMR
97 HB320 Blanchaquinone (20) Anthraquinone Antibacterial, cytotoxic MS, UV, PKS
98 HB320 Antibiotic MA 1189 (102) Benzenediol 5-Lipoxygenase inhibitor MS, UV
99 HB320 Antibiotic K 502A (125) Anthracycline ND MS, UV, PKS-specific PCR
100 HB320 Homo-nonactyl-nonactoate (94) Dilactone ND MS, UV
101 HB328 Futalosine (43) Nucleoside Cytotoxic MS, UV
102 HB328 Antibiotic X 14889A (66) Polyether Active against Gram-positive
bacteria
MS, UV
103 HB328 Mutalomycin (29) Polyether Ionophore MS, UV
104 HB375 Diazepinomicin (18) Alkaloid Antimicrobial MS, UV
105 HB375 Fortimicin AH (27) Aminocyclitol Antibacterial MS, UV
106 HB375 Rakicidin A (72) Lipopeptide Hypoxia-selective cytotoxic
agent
MS, UV
107 HB375 Rakicidin B (72) Lipopeptide Cytotoxic MS, UV
108 HB375 Polyene with ca. 12 double bonds Polyene Antifungal MS, UV
a ND, not determined.
b A PCR product of the estimated size was obtained. Sequence similarity could not be detected.
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TABLE 3. Identified metabolites from H. panicea-associated actinobacterial strains negative for a PKS and/or NRPS gene fragment by PCR
No. Source(s) Compound (reference) Chemical group Activity(ies) Dereplicationanalyses
1 HB084, HB095, HB096,
HB116, HB118
5-(6-Methyl-7-oxo-octyl)-
SH-furan-2-one (76)
Lactone Cytotoxic MS, UV, NMR
2 HB084, HB116, HB118, HB184 3-Formamido-2-hydroxy-
N-	(2R,3S,6S,7R,8R)-7-
hydroxy-2,6,8-trimethyl-
4,9-dioxo-1,5-dioxoan-
3yl
benzamide (37)
Macrolide (antimycin) NDa MS, UV
3 HB084, HB116, HB118, HB184 {3	(3-Formamido-2-
hydroxy-benzoyl)
amido
-2,6-dimethyl-4,9-
dioxo-1,5-dioxoan-7-
yl}fomate (15)
Macrolide (antimycin) ND MS, UV
4 HB084, HB116, HB118, HB184 Blastamycin (37) Macrolide (antimycin) Antifungal inhibitor of
ATP-citrate lyase
MS, UV
5 HB084, HB116, HB118, HB184 Urauchimycin A or B (46) Macrolide (antimycin) Antifungal MS, UV
6 HB084, HB116, HB118, HB184 Dehexylantimycin A1 (15) Macrolide (antimycin) ND MS, UV
7 HB084, HB095, HB096,
HB116, HB118, HB184
Antimycin A3 (8) Macrolide Cytotoxic, antiviral,
inhibitor of ATP-
citrate lyase
MS, UV, NMR
8 HB084, HB095, HB096,
HB116, HB118, HB184
Antimycin A2 (8) Macrolide Inhibitor of ATP-citrate
lyase
MS, UV, NMR
9 HB084, HB095, HB096,
HB116, HB118, HB184
Antimycin A1 (8) Macrolide Antiviral, inhibitor of
ATP-citrate lyase,
ichthyotoxin, inhibitor
of ubiquinol-
cytochrome C
oxidoreductase
MS, UV, NMR
10 HB084, HB095, HB096,
HB116, HB118
Antimycin A0 (8) Macrolide Antifungal MS, UV, NMR
11 HB095, HB096 Gentamicin C1 (12) Aminoglycoside Antibacterial MS, UV
12 HB095, HB096 Gentamicin A2 (12) Aminoglycoside Antibacterial MS, UV
13 HB095, HB184 Antimycin A4 (8) Macrolide Inhibitor of ATP-citrate
lyase
MS, UV, NMR
14 HB096 Dihydromaltophilin (34) Macrolactam Antifungal MS, UV
15 HB105 Polyene Polyketide Antifungal UV
16 HB116, HB118 Fredericamycin A (117) Aromatic polyketide Cytotoxic generator of
free radicals
MS, UV
17 HB122 Pyrocoll (22) Alkaloid Antibacterial, antifungal,
cytotoxic,
antiprotozoan,
antiparasitic
MS, UV, NMR
18 HB122 Streptazone B1 or B2 (90) Alkaloid Cytotoxic MS, UV
19 HB122 Saphenyl ester D (65) Phenazine Antibacterial MS, UV
20 HB122 Xanthobaccin A (80) Macrolactam Antifungal MS, UV
21 HB122 Aestivophoenin C (61) Phenazine Neuronal cell-protecting
agent, antioxidant
MS, UV
22 HB184 Enterocin (88) Aromatic polyketide ND MS, UV
23 HB184 trans-Cinnamic acid (15) Aromatic carboxylic
acid
ND MS, UV
24 HB184 {8-Benzyl-3-	(3-
formamido-2-
hydroxybenzoyl)amino
-
2,6-dimethyl-4,9-dioxo-
1,5-dioxonan-7-yl} 3-
methylbutanoate (15)
Macrolide (antimycin) ND MS, UV
25 HB184 Antimycin (8) Macrolide (antimycin) ND MS, UV
26 HB184 5-{3-	(3-Formamido-2-
hydroxybenzoyl)amino
-
2,6-dimethyl-8-octyl-4,9-
dioxo-1,5-dioxonan-7-yl}
pentanoic acid (37)
Macrolide (antimycin) ND MS, UV
27 HB241 Indole derivative Alkaloid ND MS, UV
a ND, not determined.
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strain HB238, which seems to be a plant growth regulator,
were detected.
Antimicrobial activities of identified metabolites compared
to crude extract activities. Overall, by comparing data on the
antimicrobial activities of the extracts (Table 4) with the data
for identified metabolites and their known bioactivities from
the literature (Tables 2 and 3), we were able to relate the
antimicrobial activities of the extracts to the corresponding
identified antimicrobial metabolites in 31 culture extracts (Ta-
ble 4). The multiple antimicrobial activities of some extracts
may be explained by the presence of antibiotics with broad
spectra of activities. Another explanation may be the occur-
rence of many different substances with complementary activ-
ities. For example, two antibacterial metabolites and, in addi-
tion, the cytotoxic compound 4-thiouracil were identified in
strain HB107 (Table 2). However, for six strains, antimicrobial
activity was measurable although substances with described
antibacterial or cytotoxic activities were not identified. For
example, strain HB132 showed activity against different bacte-
ria, but only two antifungal substances, venturicidin A and
irumamycin, were identified (Tables 2 and 4). These findings
may indicate the presence of new antibacterial compounds, an
idea which is supported by the detection of a so far unidenti-
fied substance in the extract from strain HB132. To prove the
correlation between antimicrobial activities of the crude ex-
tracts and the presence of secondary metabolites, strains
HB100, HB157, and HB288 were selected for isolation of me-
tabolites. The activities of the pure substances against our test
organisms were examined. The antimicrobial activities of the
culture extracts were congruent with those of the purified sub-
stances. For example, the extract from HB100 showed activity
against R. solanacearum, which was attributed to the oxazolo-
mycin isolated from this strain. It is already known from liter-
ature that this substance shows such activity. Extracts from
HB157 and HB288 inhibited the growth of C. glabrata, which is
consistent with the presence of antimycins A0 to A4, showing
the same activity patterns (Table 4).
DISCUSSION
Correlation between NRPS and PKS-II biosynthetic gene
fragment occurrence and secondary metabolite pattern. The
majority of Actinobacteria-derived compounds are shown to be
complex polyketides and nonribosomal peptides; nevertheless,
other metabolites and other biosynthetic pathways do exist, as
reflected in actinobacterial genomes (10, 44). It may be as-
sumed that a genome with a higher number of biosynthetic
gene clusters is more likely to result in a positive hit in an
NRPS/PKS gene screening approach. Therefore, positive re-
sults in a PCR-based screening for NRPS and PKS-II genes not
only provide evidence of the production of corresponding me-
tabolites but also may indicate the existence of further meta-
bolic pathways of secondary metabolite synthesis.
However, the lack of detectable NRPS or PKS-II gene frag-
ments does not definitely prove the absence of the respective
biosynthetic gene clusters. For example, the strains HB116,
HB118, and HB157 produced the polyketide fredericamycin A.
The biosynthetic gene cluster for this substance showed an
unusual KS domain which is not amplified by the primer
system used. Sequence comparison of the applied PKS-II prim-
ers and the fredericamycin A gene cluster did not reveal any
homology. Hence, the chosen primer system, albeit favorable
for the great majority of known PKS-II genes, is not working in
the case of aromatic polyketides with unusual molecular con-
structions. Within this study, all bacteria—except a single iso-
late—that tested positive in the genetic prescreening approach
were not only able to produce a higher number of secondary
metabolites but also provided greater diversity of structural
types and more antimicrobial activity than those strains with a
negative result for PCR amplification of PKS-II and NRPS
genes. Furthermore, the number of strains that did not pro-
duce any compound under the applied culture conditions was
also significantly higher within the group with a negative result.
For this reason, molecular screening for PKS and NRPS genes
is a valuable tool for preselection of strains for secondary
metabolite production.
FIG. 1. Comparison of the numbers of secondary metabolite-producing strains (pie diagrams) and the numbers of resulting compounds (bars)
among strains with a negative NRPS/PKS PCR result and those with a positive PCR result.
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Ecological roles of compounds: beneficial effects. Though
the abundance of microorganisms in marine sponges is well
examined, the ecological roles of secondary metabolites pro-
duced by these microorganisms are not well understood. It was
hypothesized that they may be relevant in biological interac-
tions, e.g., in defense against antagonists. In the following, the
activities of the compounds identified in the extracts from
sponge-associated Actinobacteria will be discussed from an
ecological point of view.
In the close bacterium-sponge associations, Actinobacteria
represent a large proportion of the microbial community com-
pared to the marine bacterioplankton (41, 47, 109). Actinobac-
teria display enormous potential to produce secondary metab-
olites within bacterium-invertebrate communities (16, 38, 56,
TABLE 4. Antimicrobial activities of extracts from actinobacterial strainsa
Strain
Active against: Antimicrobial activityestablished by:
S.
lentus
B.
subtilis E. coli
P.
fluorescens
C.
glabrata
P.
syringae
X.
campestris
E.
amylovora
R.
solanacearum
Testing of
extracts
Description of
identified
compounds in
the literature
HB062 X X X
HB084 X X X
HB094
HB095 X X X
HB096 X X X
HB099
HB100 Xb X
HB101
HB102 X
HB105 X X X
HB107 X X X X X X X X X
HB108
HB110
HB113 X
HB114
HB115
HB116 X X X
HB117 X X X X X X
HB118 X X X
HB122 X X X X
HB132 X X X X X X X X X
HB138 X X X X X X
HB140 X
HB142 X X X
HB149 X X X
HB156 X X X X
HB157 Xb X X
HB181 X X X
HB184 X X X X
HB200
HB202 X X X X X X X
HB238 X X X
HB241
HB243 X
HB253 X X X X X X X
HB254 X X
HB272 X X X X X X
HB274 X X X X
HB288 Xb Xb X X
HB291 X X X
HB298 X X X X X X X X X
HB320
HB328 X X X X X
HB375 X X X X X X
HB381
HB383 X X X
No. of extracts
with activity
15 20 4 3 12 4 7 4 11 31 29
% of extracts
with activity
33 44 9 7 26 9 15 9 24 67 63
a X indicates positivity for antimicrobial activity.
b Correlation between the biological assay results for crude extracts and those for purified substances was possible.
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108) and thus may contribute to the survival of the organisms
involved. One possible function of these compounds is the
chemical defense of the host (41). In the case of a sponge,
detrimental organisms range from pathogenic bacteria and
fungi to macroorganisms which colonize the surface or prey on
the sponge. The protection of H. panicea against infectious
agents or predators may be mediated by the substances which
were identified in this study, because they showed broad-spec-
trum activities, including antimicrobial and cytotoxic effects.
Antibacterial agents like the streptophenazines (produced
by strain HB202) and different streptomycins (produced by
strains HB062, HB113, and HB138) may defend Actinobacteria
and their host against other bacteria (29, 74, 116, 118).
Through the production of antifungal agents like pyrocoll (pro-
duced by strains HB117, HB122, and HB328), Actinobacteria
defend themselves against fungi in their environment. Fungi
are competitors for nutrients and also produce antibacterial
substances. Many of the secondary metabolites identified in
the Actinobacteria associated with H. panicea are cytotoxic:
streptazone B1 (90) (produced by strains HB117, HB122, and
HB291), fredericamycin A (117) (produced by strains HB116,
HB118, and HB157), and daryamide C (7) (produced by strain
HB272). These substances may be protective against different
eukaryotic antagonists like protists or vertebrates. They also
may serve as protective agents against digestion of the bacteria
by the sponge itself. Insecticides and other agents against ver-
tebrates and invertebrates, like antimycin A1 (8) (produced by
strains HB157, HB181, and HB288) and bafilomycin (60) (pro-
duced by strain HB181), as well as streptomycin (116) (pro-
duced by strain HB113), may defend the sponge from preda-
tors. Antioxidative agents like aestivophoenin C (produced by
strain HB122) may shield the sponge against the oxidation of
sensitive molecules (61) and protect the cell nucleus and the
cell membrane from these “scavengers.” However, many re-
dox-active secondary metabolites may have additional and rel-
evant properties independent from their antioxidant/radical-
scavenging activities. One example is a modulation of colony
morphology by phenazines of Pseudomonas aeruginosa (23),
but antibiotic activities and cell-cell-signaling functions have
been reported as well. Therefore, antioxidant agents may also
play a role in the regulation of growth and the composition of
biofilms in H. panicea. Phytotoxic compounds and algicides
may prevent the sponge from periphyton algae (53, 104). An
example of such a substance is oxazolomycin (produced by
strain HB100). Pyrocoll (produced by strains HB117, HB122,
and HB328) and other antiprotozoan agents such as antibiotic
X 14931A (produced by strain HB113) may protect the bacte-
ria against digestion by protozoans (22). In summary, the sub-
stances produced by Actinobacteria possibly could participate
in maintaining the balance of microbial biofilms within and on
the sponge by preventing growth of deleterious microorgan-
isms.
Ecological roles of compounds: deleterious effects. Beside
beneficial interactions, some of the produced substances may
exhibit deleterious effects on the sponge. For example, strain
HB181 synthesized bafilomycin D, which inhibits ATPase (60).
Analyses of the strains HB117, HB122, HB181, HB291, and
HB328 revealed the presence of the cytotoxic compounds se-
nacarcin A (79) and pyrocoll (22). All these activities may
affect not only potential predators but also the sponge. Known
potential virulence factors in sponges are produced by fungi,
viruses, cyanobacteria, and bacteria of the genera Bacillus and
Pseudomonas (119). In one case, a novel alphaproteobacte-
rium was identified as the primary pathogen (119). Up to now,
Actinobacteria have not been described as sponge pathogens,
and we assume that the secondary metabolites produced by
Actinobacteria associated with H. panicea rather have benefi-
cial effects.
Biological sources of the substances. An increasing number
of compounds originally thought to be biosynthesized by the
sponges are actually produced by sponge-associated bacteria
(89), e.g., the peptide thiocoraline, produced by a Micromono-
spora species (97). This inevitably raises the question of
whether sponge-associated Actinobacteria provide a number of
metabolites whose production has been attributed to sponges
before. Nearly all compounds from Actinobacteria strains iso-
lated from H. panicea that we have identified within our study
were known as bacterial products. In only two cases are the
reported results ambiguous: 1-epimanzamine D, which was
originally isolated from a Palaun sponge and was produced by
strain HB113, identified as Streptomyces fulvorobeus (127), and
coproporphyrin, produced by strain HB100 (113), were de-
scribed previously as products of sponges (coproporphyrin was
also identified as a product of bacteria). It remains unknown
whether all of the substances produced by Actinobacteria in
laboratory cultures are also synthesized in the sponge habitat,
what factors are essential for production, and whether the
compounds will be produced in sufficient amounts to interact
with the environment. Here, it is important that microbial
secondary metabolites have been proposed to act as signaling
molecules at subinhibitory concentrations. Thus, it is not ex-
pected that these compounds are produced at inhibitory levels.
So far, some bacterium-derived substances have been isolated
from sponge tissue (55, 87, 89), which may be taken as evi-
dence that their concentrations are sufficient to be biologically
active in situ. A specific cocktail of chemical substances that is
strongly dependent on environmental factors is expected to
occur. Hence, only a small selected fraction of the secondary
metabolites of Actinobacteria will be expressed at a given time.
Within this context, it is of special interest that the first chem-
ical analysis of crude extract from H. panicea revealed the
occurrence of antimicrobially active substances identified in
the sponge-associated Micromonospora sp. strain HB243. In
conclusion, some of the substances identified in sponge-asso-
ciated Actinobacteria are definitely produced within the sponge
in sufficient amounts to display their biological activities. De-
pending on the environmental conditions, we expect that most
of the other compounds described in this work, if not all, may
have their roles in the complex sponge system.
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